140 related articles for article (PubMed ID: 27177670)
1. mRNA Transfection to Improve NK Cell Homing to Tumors.
Levy ER; Carlsten M; Childs RW
Methods Mol Biol; 2016; 1441():231-40. PubMed ID: 27177670
[TBL] [Abstract][Full Text] [Related]
2. Enhanced Bone Marrow Homing of Natural Killer Cells Following mRNA Transfection With Gain-of-Function Variant CXCR4
Levy E; Reger R; Segerberg F; Lambert M; Leijonhufvud C; Baumer Y; Carlsten M; Childs R
Front Immunol; 2019; 10():1262. PubMed ID: 31231387
[TBL] [Abstract][Full Text] [Related]
3. Engineering lymph node homing of ex vivo-expanded human natural killer cells via trogocytosis of the chemokine receptor CCR7.
Somanchi SS; Somanchi A; Cooper LJ; Lee DA
Blood; 2012 May; 119(22):5164-72. PubMed ID: 22498742
[TBL] [Abstract][Full Text] [Related]
4. Modification of Expanded NK Cells with Chimeric Antigen Receptor mRNA for Adoptive Cellular Therapy.
Chu Y; Flower A; Cairo MS
Methods Mol Biol; 2016; 1441():215-30. PubMed ID: 27177669
[TBL] [Abstract][Full Text] [Related]
5. Viral and Nonviral Engineering of Natural Killer Cells as Emerging Adoptive Cancer Immunotherapies.
Matosevic S
J Immunol Res; 2018; 2018():4054815. PubMed ID: 30306093
[TBL] [Abstract][Full Text] [Related]
6. Large volume flow electroporation of mRNA: clinical scale process.
Li L; Allen C; Shivakumar R; Peshwa MV
Methods Mol Biol; 2013; 969():127-38. PubMed ID: 23296932
[TBL] [Abstract][Full Text] [Related]
7. Transpresentation of interleukin-15 by IL-15/IL-15Rα mRNA-engineered human dendritic cells boosts antitumoral natural killer cell activity.
Van den Bergh J; Willemen Y; Lion E; Van Acker H; De Reu H; Anguille S; Goossens H; Berneman Z; Van Tendeloo V; Smits E
Oncotarget; 2015 Dec; 6(42):44123-33. PubMed ID: 26675759
[TBL] [Abstract][Full Text] [Related]
8. Human CAR NK Cells: A New Non-viral Method Allowing High Efficient Transfection and Strong Tumor Cell Killing.
Ingegnere T; Mariotti FR; Pelosi A; Quintarelli C; De Angelis B; Tumino N; Besi F; Cantoni C; Locatelli F; Vacca P; Moretta L
Front Immunol; 2019; 10():957. PubMed ID: 31114587
[TBL] [Abstract][Full Text] [Related]
9. Improving efficacy of cancer immunotherapy by genetic modification of natural killer cells.
Burga RA; Nguyen T; Zulovich J; Madonna S; Ylisastigui L; Fernandes R; Yvon E
Cytotherapy; 2016 Nov; 18(11):1410-1421. PubMed ID: 27421740
[TBL] [Abstract][Full Text] [Related]
10. Ex vivo expansion of highly cytotoxic human NK cells by cocultivation with irradiated tumor cells for adoptive immunotherapy.
Lim SA; Kim TJ; Lee JE; Sonn CH; Kim K; Kim J; Choi JG; Choi IK; Yun CO; Kim JH; Yee C; Kumar V; Lee KM
Cancer Res; 2013 Apr; 73(8):2598-607. PubMed ID: 23580577
[TBL] [Abstract][Full Text] [Related]
11. Delivery of DNA into natural killer cells for immunotherapy.
Schoenberg K; Trompeter HI; Uhrberg M
Methods Mol Biol; 2008; 423():165-72. PubMed ID: 18370197
[TBL] [Abstract][Full Text] [Related]
12. Characterization of natural killer and natural killer-like T cells derived from ex vivo expanded and activated cord blood mononuclear cells: implications for adoptive cellular immunotherapy.
Ayello J; van de Ven C; Cairo E; Hochberg J; Baxi L; Satwani P; Cairo MS
Exp Hematol; 2009 Oct; 37(10):1216-29. PubMed ID: 19638292
[TBL] [Abstract][Full Text] [Related]
13. Ex vivo expansion of the highly cytotoxic human natural killer-92 cell-line under current good manufacturing practice conditions for clinical adoptive cellular immunotherapy.
Tam YK; Martinson JA; Doligosa K; Klingemann HG
Cytotherapy; 2003; 5(3):259-72. PubMed ID: 12850795
[TBL] [Abstract][Full Text] [Related]
14. Expression of chimeric antigen receptors in natural killer cells with a regulatory-compliant non-viral method.
Li L; Liu LN; Feller S; Allen C; Shivakumar R; Fratantoni J; Wolfraim LA; Fujisaki H; Campana D; Chopas N; Dzekunov S; Peshwa M
Cancer Gene Ther; 2010 Mar; 17(3):147-54. PubMed ID: 19745843
[TBL] [Abstract][Full Text] [Related]
15. Genetic engineering of human NK cells to express CXCR2 improves migration to renal cell carcinoma.
Kremer V; Ligtenberg MA; Zendehdel R; Seitz C; Duivenvoorden A; Wennerberg E; Colón E; Scherman-Plogell AH; Lundqvist A
J Immunother Cancer; 2017 Sep; 5(1):73. PubMed ID: 28923105
[TBL] [Abstract][Full Text] [Related]
16. Expanded and armed natural killer cells for cancer treatment.
Shimasaki N; Coustan-Smith E; Kamiya T; Campana D
Cytotherapy; 2016 Nov; 18(11):1422-1434. PubMed ID: 27497701
[TBL] [Abstract][Full Text] [Related]
17. Engineering Receptor Expression on Natural Killer Cells Through Trogocytosis.
Somanchi A; Lee DA; Somanchi SS
Methods Mol Biol; 2016; 1441():253-65. PubMed ID: 27177672
[TBL] [Abstract][Full Text] [Related]
18. Characterization of stem cell factor gene-modified human natural killer cell line, NK-92 cells: implication in NK cell-based adoptive cellular immunotherapy.
Zhang J; Sun R; Wei H; Zhang J; Tian Z
Oncol Rep; 2004 May; 11(5):1097-106. PubMed ID: 15069553
[TBL] [Abstract][Full Text] [Related]
19. Characterization of genetically altered, interleukin 2-independent natural killer cell lines suitable for adoptive cellular immunotherapy.
Tam YK; Maki G; Miyagawa B; Hennemann B; Tonn T; Klingemann HG
Hum Gene Ther; 1999 May; 10(8):1359-73. PubMed ID: 10365666
[TBL] [Abstract][Full Text] [Related]
20. Cellular immunotherapy of malignancies using the clonal natural killer cell line NK-92.
Tonn T; Becker S; Esser R; Schwabe D; Seifried E
J Hematother Stem Cell Res; 2001 Aug; 10(4):535-44. PubMed ID: 11522236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
